ZYME
Zymeworks Inc. NASDAQ Listed Apr 28, 2017$26.52
-1.08%
vs $26.81
Mkt Cap $2.0B
52w Low $16.00
68.6% of range
52w High $31.34
50d MA $25.85
200d MA $25.08
P/E (TTM)
—
EV/EBITDA
—
P/B
7.4x
Debt/Equity
0.1x
ROE
-30.2%
P/FCF
-57.9x
RSI (14)
34.70
ATR (14)
$0.99
Beta
1.20
50d MA
$25.85
200d MA
$25.08
Avg Volume
737.2K
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
114 East 4th Avenue · Middletown, BC V5T 1G4 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -0.57 | -0.62 | -9.2% | 23.13 | +4.2% | +1.8% | +2.6% | +0.7% | +2.5% | +3.3% | — |
| May 7, 2026 | AMC | -0.10 | -0.59 | -490.0% | 26.60 | -1.5% | -10.2% | +0.6% | -0.5% | +2.8% | -2.5% | — |
| Mar 2, 2026 | AMC | -0.35 | -0.55 | -57.1% | 23.31 | +2.1% | +4.9% | +3.2% | -1.7% | -2.9% | +0.7% | — |
| Nov 6, 2025 | AMC | -0.30 | -0.26 | +13.3% | 17.90 | -5.0% | -8.0% | +9.7% | +9.0% | -1.6% | -4.5% | — |
| Aug 7, 2025 | AMC | -0.52 | 0.03 | +105.8% | 12.16 | +2.3% | -1.2% | +3.5% | +4.7% | +7.1% | +2.6% | — |
| May 8, 2025 | AMC | -0.45 | -0.30 | +33.3% | 11.32 | +0.5% | -0.1% | +6.3% | -3.4% | -3.1% | +2.5% | — |
| Mar 5, 2025 | AMC | 0.01 | -0.31 | -3200.0% | 13.18 | -5.6% | -8.0% | -1.1% | -7.5% | +5.4% | +5.0% | — |
| Oct 31, 2024 | AMC | -0.40 | -0.39 | +2.5% | 13.70 | -6.8% | -3.1% | +11.1% | -0.7% | +6.5% | +7.4% | — |
| Aug 1, 2024 | AMC | -0.42 | -0.49 | -17.4% | 10.11 | +4.8% | +0.9% | -2.0% | +1.5% | -3.2% | +3.8% | — |
| May 2, 2024 | AMC | -0.31 | -0.42 | -35.5% | 9.00 | -1.8% | +2.2% | -1.5% | +0.7% | -0.7% | +1.9% | — |
| Mar 6, 2024 | AMC | -0.39 | -0.20 | +48.7% | 12.23 | -6.9% | -6.5% | +0.0% | -3.4% | -2.2% | -0.6% | — |
| Nov 7, 2023 | AMC | -0.55 | -0.41 | +25.5% | 7.37 | +2.6% | -3.7% | -2.1% | +4.9% | -0.3% | +5.0% | — |
| Aug 10, 2023 | AMC | -0.51 | -0.76 | -49.0% | 7.76 | -9.8% | -7.6% | +4.5% | -0.9% | -2.0% | +1.1% | — |
| May 8, 2023 | AMC | -0.64 | -0.37 | +42.2% | 8.76 | +11.8% | +12.8% | -1.9% | +3.0% | -1.2% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17 | Wolfe Research | Initiates | Outperform | — | $26.24 | $27.15 | +3.5% | +4.7% | -3.3% | +0.9% | +2.8% | -0.3% |
| Aug 26 | H.C. Wainwright | Reiterates | Buy | $55 | $27.47 | $27.56 | +0.3% | +6.7% | -1.0% | -2.6% | +4.0% | +0.9% |
| Jun 9 | Truist | Reiterates | Buy | $28 | $23.93 | $24.41 | +2.0% | -2.8% | -1.8% | +0.5% | -0.4% | +1.7% |
| Mar 9 | Evercore ISI | Maintains | Outperform → Outperform | — | $24.08 | $23.88 | -0.8% | +0.7% | +5.0% | -1.3% | -7.6% | -1.5% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $25.09 | +1.2% | -2.9% | +0.7% | +5.0% | -1.3% | -7.6% |
| Mar 3 | Stifel | Maintains | Buy → Buy | — | $23.31 | $23.80 | +2.1% | +4.9% | +3.2% | -1.7% | -2.9% | +0.7% |
| Mar 3 | Leerink Partners | Maintains | Outperform → Outperform | — | $23.31 | $23.80 | +2.1% | +4.9% | +3.2% | -1.7% | -2.9% | +0.7% |
| Dec 12 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $24.94 | $26.28 | +5.4% | +2.2% | +1.9% | -0.5% | -1.0% | +3.2% |
| Nov 21 | B. Riley Securities | Maintains | Buy → Buy | — | $23.82 | $23.82 | +0.0% | +0.8% | +4.0% | +4.8% | +4.4% | -2.3% |
| Nov 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $22.99 | $23.01 | +0.1% | -1.7% | +5.4% | +0.8% | +4.0% | +4.8% |
| Nov 19 | Stifel | Maintains | Buy → Buy | — | $22.99 | $23.01 | +0.1% | -1.7% | +5.4% | +0.8% | +4.0% | +4.8% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.90 | $24.28 | +1.6% | -3.8% | -1.7% | +5.4% | +0.8% | +4.0% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.90 | $17.01 | -5.0% | -8.0% | +9.7% | +9.0% | -1.6% | -4.5% |
| Oct 16 | JP Morgan | Maintains | Overweight → Overweight | — | $18.62 | $18.94 | +1.7% | -0.4% | -0.8% | -0.4% | -2.1% | -1.4% |
| Oct 14 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $18.11 | $18.96 | +4.7% | +0.7% | +2.1% | -0.4% | -0.8% | -0.4% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $12.02 | $12.32 | +2.5% | +3.5% | +4.7% | +7.1% | +2.6% | +0.4% |
| Jul 3 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.89 | $12.96 | +0.5% | +1.2% | +0.3% | -1.0% | +4.8% | +0.7% |
| Mar 10 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $12.00 | $11.77 | -1.9% | -7.5% | +5.4% | +5.0% | +2.2% | -2.4% |
| Mar 7 | Citigroup | Maintains | Buy → Buy | — | $12.13 | $12.21 | +0.7% | -1.1% | -7.5% | +5.4% | +5.0% | +2.2% |
| Dec 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.74 | $12.91 | +1.3% | +6.6% | +4.1% | +1.0% | -1.0% | +2.5% |
| Dec 16 | JP Morgan | Upgrade | Neutral → Overweight | — | $12.58 | $13.47 | +7.1% | +9.5% | -2.9% | -4.7% | +6.6% | +4.1% |
| Nov 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.68 | $13.74 | +0.4% | +4.5% | -0.6% | +0.7% | +0.8% | -2.3% |
| Nov 7 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $15.61 | $16.37 | +4.9% | +7.4% | -0.8% | +4.2% | +0.4% | -1.1% |
| Nov 4 | Citigroup | Maintains | Buy → Buy | — | $13.28 | $13.30 | +0.2% | +11.1% | -0.7% | +6.5% | +7.4% | -0.8% |
| Nov 1 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $13.70 | $12.77 | -6.8% | -3.1% | +11.1% | -0.7% | +6.5% | +7.4% |
| Nov 1 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.70 | $12.77 | -6.8% | -3.1% | +11.1% | -0.7% | +6.5% | +7.4% |
| Oct 28 | Stifel | Maintains | Buy → Buy | — | $12.93 | $13.27 | +2.6% | +2.4% | +3.5% | +1.2% | -1.2% | -3.1% |
| Aug 2 | Stifel | Maintains | Buy → Buy | — | $10.11 | $10.60 | +4.8% | +0.9% | -2.0% | +1.5% | -3.2% | +3.8% |
| Jun 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.92 | $8.99 | +0.8% | +2.0% | -0.3% | -1.1% | +7.1% | -2.6% |
| May 7 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.06 | $9.02 | -0.4% | +0.7% | -0.7% | +1.9% | -4.6% | +4.9% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $9.00 | $8.84 | -1.8% | +2.2% | -1.5% | +0.7% | -0.7% | +1.9% |
| May 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $9.00 | $8.84 | -1.8% | +2.2% | -1.5% | +0.7% | -0.7% | +1.9% |
| Mar 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.05 | $11.15 | +0.9% | -2.2% | -0.6% | +0.2% | +0.4% | -0.9% |
| Mar 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $11.44 | $11.47 | +0.3% | -3.4% | -2.2% | -0.6% | +0.2% | +0.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.49 | $7.47 | -0.3% | -0.9% | -2.0% | +1.1% | +1.0% | +3.1% |
| Jun 6 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.94 | $8.97 | +0.3% | -1.5% | +0.9% | -1.8% | -2.4% | -1.9% |
| Jun 2 | Citigroup | Maintains | Buy → Buy | — | $8.49 | $8.50 | +0.1% | +2.1% | +3.1% | -1.5% | +0.9% | -1.8% |
| May 18 | Citigroup | Maintains | Buy → Buy | — | $9.19 | $9.24 | +0.5% | +4.4% | +1.9% | -5.9% | +0.2% | -4.5% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $8.76 | $9.79 | +11.8% | +12.8% | -1.9% | +3.0% | -1.2% | -0.4% |
| Mar 31 | JP Morgan | Maintains | Neutral → Neutral | — | $8.76 | $8.90 | +1.6% | +3.2% | +3.7% | +0.3% | +0.1% | -0.2% |
| Mar 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.52 | $8.61 | +1.1% | +4.7% | -6.1% | -2.3% | +0.1% | -1.2% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $8.08 | $8.03 | -0.6% | -1.9% | +4.0% | +2.7% | +1.9% | -3.8% |
| Mar 8 | Guggenheim | Maintains | Buy → Buy | — | $7.96 | $8.60 | +8.0% | +0.5% | +1.0% | -1.9% | +4.0% | +2.7% |
| Jan 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.41 | $9.87 | +4.9% | +4.4% | -0.4% | -0.3% | -1.7% | -0.4% |
| Jan 20 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $9.68 | $9.85 | +1.8% | +3.3% | -5.9% | +4.4% | -0.4% | -0.3% |
| Jan 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.54 | $7.63 | +1.2% | +1.7% | +4.3% | -4.4% | -1.4% | +3.4% |
| Dec 22 | Barclays | Maintains | Equal Weight → Equal Weight | — | $8.75 | $8.75 | +0.0% | +0.5% | -8.5% | -6.8% | +0.0% | +4.3% |
| Dec 20 | Jefferies | Upgrade | Hold → Buy | — | $6.79 | $7.07 | +4.1% | +4.3% | +23.6% | +0.5% | -8.5% | -6.8% |
| Nov 21 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.76 | $7.84 | +1.0% | +2.4% | -2.4% | +3.6% | -2.5% | -0.1% |
| Nov 1 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.43 | $7.26 | -2.3% | +0.3% | -5.6% | +4.7% | +8.4% | -0.4% |
No insider trades available.
8-K · 7.01
! Medium
Zymeworks Inc. -- 8-K 7.01: Regulation FD Disclosure
Aug 25
8-K
Zymeworks Inc. -- 8-K Filing
Zymeworks Inc. filed an 8-K on August 6 disclosing material non-public information under Items 2.02 and 7.01, though the specific business details warrant investor review of the attached exhibits.
Aug 6
8-K
Zymeworks Inc. -- 8-K Filing
Zymeworks shareholders will receive per-share cash consideration plus contingent value rights in a merger transaction, with payouts dependent on future milestones outlined in the CVR agreement.
Jun 29
8-K
Unknown — 8-K Filing
ZYME's new Chief Financial Officer appointment signals potential leadership restructuring that investors should monitor for strategic direction changes and financial management quality improvements.
Apr 1
8-K
Zymeworks Inc. -- 8-K Filing
Zymeworks Inc. filed an 8-K providing updates under Items 2.02 and 7.01, though specific financial details or material events are not disclosed in this summary excerpt.
Mar 2
8-K · 1.01
! Medium
Zymeworks Inc. -- 8-K 1.01: Financing / Debt Agreement
Zymeworks secured $250 million in royalty-backed financing through Zymeworks Royalty Limited Partners, providing capital to fund operations and development while leveraging future revenue streams.
Mar 2
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.95B
Enterprise Value
$1.77B
P/E (TTM)
—
Forward P/E
22.36x
PEG Ratio
0.73x
P/B
7.44x
P/S
52.55x
P/FCF
-57.87x
EV/EBITDA
—
Shares Out
75.3M
Financials (TTM)
Revenue
$37.1M
Net Income
-$150.0M
EBITDA
-$139.9M
Free Cash Flow
-$34.5M
Op Cash Flow
-$33.0M
EPS Basic
$-1.08
EPS Diluted
$-2.02
EPS Forward
$1.19
Gross Margin
87.8%
Op Margin
-419.0%
Net Margin
-404.0%
Balance Sheet
Total Assets
$346.5M
Total Liab.
$78.0M
Total Equity
$268.5M
Cash
$228.8M
LT Debt
$0
Book Value/Sh
$3.56
Debt/Equity
0.07x
Current Ratio
5.52
Quick Ratio
5.52
Returns & Growth
ROE
-30.2%
ROA
-23.4%
ROIC
-30.1%
Rev Growth YoY
+38.9%
EPS Growth YoY
+33.3%
Price Returns
2W
+1.1%
1M
-9.5%
3M
+9.8%
6M
+7.4%
12M
+59.8%
Technicals
52W High
$31.34
52W Low
$16.00
50d MA
$25.85
200d MA
$25.08
RSI (14)
34.70
ATR (14)
$0.99
Beta
1.20
Avg Volume
737K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$38.33
High
$48.00
Low
$32.00
Median
$38.50
Data updated apr 27, 2026 11:55am
· Source: financialmodelingprep.com